SUNNYVALE, Calif., Feb. 5, 2020 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that two new studies
demonstrate the benefits of the TomoTherapy®
System in the treatment of advanced rectal cancer.
Radiotherapy, with or without chemotherapy, followed by surgery is
the standard of care in the treatment of locally, advanced rectal
cancer. However, radiation delivered to surrounding organs, such as
the bowel and bladder, may lead to life-changing side effects,
making it critically important for the radiation to be delivered
with extreme accuracy and precision. The TomoTherapy platform,
including the next-generation Radixact® System, is
the only system available that is capable of helical radiation
delivery — continuously delivering image-guided,
intensity-modulated radiation therapy (IG-IMRT) from a full 360
degrees around the patient as the treatment table also moves
— providing greater control of the radiation dose so it
conforms precisely to the tumor and minimizes dose to healthy
tissue.
Patients enrolled in the two studies received simultaneous daily
radiation and a targeted radiation boost over a 25-day time period.
The study investigators found that the TomoTherapy platform's
unique architecture enabled the delivery of a high dose of
radiation, directly to the tumor, through the integrated boost of
radiation, while minimizing radiation to organs in close proximity
to the targeted tumor. As a result, patients in the studies
experienced improved treatment results and reduced side effects.
These study outcomes compare favorably to conventional
radiotherapy, based on results from other studies.
Study Highlights
Novel treatment approach shows promising results
The
clinical teams at Centre Hospitalier Universitaire Vaudois (CHUV)
in Lausanne, Switzerland and the
Clinica Luganese in Lugano, Switzerland, reported on their retrospective
analysis of patients with advanced rectal cancer treated with
TomoHelical™. The study titled, "Neoadjuvant chemoradiotherapy
delivered with helical tomotherapy under daily image guidance for
rectal cancer patients: efficacy and safety in a large,
multi-institutional series," was published in the Journal of
Cancer Research and Clinical Oncology, and found:
- Treatment with TomoHelical is safe, with low rates of severe
toxicity
-
- Radiation delivered with helical TomoTherapy following daily
imaging with the platform's integrated imaging capabilities allowed
for the reduction of treatment margins around the tumor, so less
normal tissue was irradiated. The authors highlight a "clear
reduction in the rates of acute and late non-hematological
toxicities" when compared to a randomized trial evaluating the use
of 2D- or conformal 3D-RT techniques, published in the New
England Journal of Medicine (NEJM)[1]
- The four-year outcomes showed excellent local tumor control and
disease-free survival rates of 88.4 percent and 74.6 percent,
respectively
- A significantly higher rate of pathological complete response
(pCR) was reported in the group of patients who received a
simultaneous integrated boost compared to those who did not receive
the boost. pCR is an indication of how well the treatment is
working, with those patients achieving a pCR experiencing reduced
rates of local recurrence and better overall survival
"The results of our analysis are encouraging because they
indicate that patients with advanced rectal cancer may have a
better option for effectively treating their disease. Further
studies are needed, however we believe that highly conformal
radiation doses delivered with TomoHelical in combination with
daily image guidance may become the new standard of care for
pre-surgical treatment in patients with advanced rectal cancer,"
said Dr. Berardino De Bari,
assistant professor and radiation oncologist in the radiation
oncology department, CHUV.
Listen to Dr. De Bari share his experience using the TomoTherapy
System at this link.
Targeted radiation boost helps maintain patient quality of
life
In another study, clinicians at Peking Union Medical
College Hospital, Chinese Academy of Medical Sciences & Peking
Union Medical College in Beijing,
People's Republic of China, published results of their
advanced rectal cancer study titled, "Concomitant dose escalation
with image-guided TomoTherapy® in locally advanced
mid-low rectal cancer: a single-center study," in Cancer
Management and Research. Highlights of the study include:
- The clinical team used TomoHelical™ to simultaneously deliver
daily radiation treatments and a targeted radiation dose boost to
the primary tumor, to improve outcomes and quality of life in
patients with advanced rectal cancer
- TomoHelical treatment was able to significantly reduce the
volume of the tumor, while minimizing dose to surrounding
organs-at-risk. This enabled surgeons to perform
sphincter-preserving surgery while removing the remaining tumor in
80.1 percent of patients in the study, thereby increasing the
chance of maintaining normal bowel function and preserving quality
of life
- Treatment resulted in positive outcomes with 95.5 percent of
patients showing local tumor control and 70.9 percent exhibiting no
signs of cancer five years after the radiation therapy
procedure
- At the study authors' institution, the outcomes associated with
TomoHelical treatment were superior to that with their
non-dose-escalated conventional approach
"Surgical treatment of mid-low rectal cancer offers the best
option for long-term management of the disease, though can be
challenging because of the risk of damaging surrounding organs and
the resulting side effects, including bleeding, fecal incontinence,
sexual and urinary dysfunction, and pelvic pain," said Fuquan Zhang [professor and chairman of the
radiation oncology department]. "With the simultaneous use of daily
radiation and a targeted boost, delivered with TomoHelical, we were
able to effectively reduce the tumor volume while preserving the
sphincter and its functionality for the majority of patients in the
study," continued Ke Hu [professor
and vice chairman of the radiation oncology department].
Listen to Prof. Zhang share his experience using the TomoTherapy
System at this link.
"These most recent studies are a valuable addition to the
available literature on the use of chemoradiation prior to surgery
in the treatment of advanced rectal cancer. The treatment outcomes
are extremely promising and may offer new hope to patients whose
previous options were limited," said Fabienne
Hirigoyenberry-Lanson, Ph.D., vice president global medical and
scientific affairs, at Accuray. "The treatment regimens described
in the studies reinforce the benefits of the unique capabilities of
the TomoTherapy platform and what we would also expect to see with
the Radixact® System. With TomoHelical mode, clinical
teams were able to effectively and efficiently treat the rectal
tumors while minimizing side effects and importantly, their
potential impact on quality of life."
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to highly conformal radiation
doses delivered with TomoHelical becoming the new standard of care
for certain patients, expecting to see the benefits of the unique
capabilities of the TomoTherapy platform in the Radixact System,
clinical applications, clinical results, patient experiences and
outcomes, and Accuray's leadership position in radiation oncology
innovation and technologies. These forward-looking statements
involve risks and uncertainties. If any of these risks or
uncertainties materialize, or if any of the company's assumptions
prove incorrect, actual results could differ materially from the
results expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, the
company's ability to achieve widespread market acceptance of its
products, including new product offerings and improvements; the
company's ability to develop new products or improve existing
products to meet customers' needs; the company's limited long-term
clinical data supporting the safety and efficacy of its products,
including product improvements, for certain users and such other
risks identified under the heading "Risk Factors" in the company's
quarterly report on Form 10-Q, filed with the Securities and
Exchange Commission (the "SEC") on November
6, 2019, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media
Contacts
|
|
Beth
Kaplan
|
Jayme
Maniatis
|
Public Relations
Director, Accuray
|
MSLGROUP
|
+1 (408)
789-4426
|
+1 (781)
684-0770
|
bkaplan@accuray.com
|
accuray@mslgroup.com
|
___________________________
1 Sauer R, et al: Preoperative versus Postoperative
Chemoradiotherapy for Rectal Cancer. N Engl J Med. 2004 Oct
21;351(17):1731-40.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/studies-support-use-of-the-accuray-tomotherapy-system-for-advanced-rectal-cancer-to-improve-treatment-efficacy-and-reduce-side-effects-300999198.html
SOURCE Accuray Incorporated